within Pharmacolibrary.Drugs.ATC.A;

model A04AA03_1
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.55,
    adminDuration  = 600,
    adminMass      = 0.005,
    adminCount     = 1,
    Vd             = 0.164,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Tropisetron is a selective 5-HT3 receptor antagonist used primarily to prevent nausea and vomiting caused by chemotherapy, radiotherapy, and surgery. It is approved for use in several countries but is less widely used today compared to other antiemetics such as ondansetron.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after intravenous administration.</p><h4>References</h4><ol><li>Rachel Huddart, Russ B Altman, Teri E Klein,PharmGKB summary: Ondansetron and tropisetron pathways, pharmacokinetics and pharmacodynamics.,Pharmacogenetics and genomics,2019<a href='https://pubmed.ncbi.nlm.nih.gov/30672837/'>https://pubmed.ncbi.nlm.nih.gov/30672837/</a></li><li>K Kutz,Pharmacology, toxicology and human pharmacokinetics of tropisetron.,Annals of oncology : official journal of the European Society for Medical Oncology,1993<a href='https://pubmed.ncbi.nlm.nih.gov/8363993/'>https://pubmed.ncbi.nlm.nih.gov/8363993/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A04AA03_1;
